The human microbiome is central to understanding inflammation, chronic diseases, and obesity, with exciting clinical applications emerging.
- Human microbiome studies are uncovering how it can influence inflammation, chronic diseases, and obesity, leading to promising clinical applications like FMT for CDI.
- Sahil Khanna, a professor at Mayo Clinic, spoke about the potential role of the gut microbiome in obesity treatment at the Obesity Medicine conference.
- Research indicates a correlation between the loss of gut microbiome diversity and the obesity pandemic, particularly in Western populations.
- Studies are exploring if specific bacterial groups can be modulated to improve metabolism and if changes in the microbiome can impact the gut-brain axis and cravings for certain foods.
- Various microbiome-based treatment options for obesity are being researched, including FMT, but further research is needed to determine their efficacy and potential adjunct therapies.
Source link
Gastroenterology, Obesity, Microbiome